TOYOPEARL GigaCap DEAE - PUSHING THE PRODUCTIVITY OF ANION EXCHANGE STEPS - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

TOYOPEARL GigaCap DEAE - PUSHING THE PRODUCTIVITY OF ANION EXCHANGE STEPS


TOYOPEARL GigaCap DEAE - PUSHING THE PRODUCTIVITY OF ANION EXCHANGE STEPS

Tosoh Bioscience is introducing a new weak anion exchanger that offers a very high dynamic binding capacity while maintaining good peak resolution. Besides other applications this is of special interest for the purification of plasma proteins.

TOYOPEARL GigaCap DEAE-650 is the newest member of the renowned TOYOPEARL GigaCap series of high capacity ion exchange media. The polymeric base bead was chemically modified to provide a high number of anionic binding sites for increased resin capacity. The typical dynamic binding capacity (DBC) of over 150 g/L for bovine serum albumin exceeds the DBC of all other commercial available DEAE chromatography media. The resin was proved to be stable for more than 100 cleaning-in-place (CIP) cycles with 0.5 M NaOH. Good mass transfer kinetics enable the resin to maintain DBC at faster linear velocities and leads to a narrow elution peak. This results in smaller and more concentrated in-process pool volumes, thus reducing the amount of water and buffer needed. The high capacity and low back pressure creates opportunities for increased throughput in various anion exchange purification steps and is ideally suited for efficient plasma protein purification.

Contact:

TOSOH BIOSCIENCE GmbH
Zettachring 6 70567 Stuttgart, Germany
Tel. +49 (0)711 13257-0
Fax: +49 (0)711 13257-89

sales-marketing.tbg@tosoh.com

www.separations.eu.tosohbioscience.com/Products/ProcessMedia/ByMode/IEC/ToyopearlGigaCapDEAE-650M.htm

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here